Sulbactomax, a research product of Venus Remedies, has been successfully out licensed to one of the top 10 pharma companies in South Korea. Korean party has been given Exclusive Marketing Rights for the whole life of patent. As per the agreement, terms the product will be supplied from Venus' Baddi unit, which is accredited with multiple international GMPs. The company has already initiated product registration process through their collaborators. Commercial supplies are expected to begin early 2011.

Sulbactomax, the innovative product developed to overcome the challenge of antibiotic resistance, is indicated mainly for LRTI and pre-post surgical infections caused by wide range of ESBL producing cephalosporin resistant strains. LRTI is a common condition posing a heavy economy burden to the health care system, especially when hospitalization is required.

Post-operative Surgical Site Infections are the most common health care-associated infection, occurring in up to five per cent of surgical patients. Treatment of the infections caused by ESBL-producing organisms is difficult, not only because of the resistance to the extended-spectrum cephalosporins themselves, but also because they are often associated with resistance to other antimicrobial agents coded either by the same or different plasmids.

Sulbactomax provides solution to chronic problem of ESBL producing resistant strains by widening the antibacterial spectrum and reducing treatment time. It additionally helps in better tissue penetration and reduces drug and disease induced side effects, thereby giving better patients compliance.

South Korea's US$14.75 billion pharmaceutical market growing at compound annual growth rate (CAGR) of 8.56 per cent, is one of the most promising in the world. Sulbactomax will have a significant market share out of the present cephalosporin market size of US$585 million in South Korea, growing at 10 per cent per annum.

This is first successful out licensing by Venus Medicine Research Centre. Earlier Venus Remedies has received patent of Sulbactomax from South African Patent office. Venus is searching for suitable partner in South African market also. The out licensing will open doors for other potential collaborators. With this deal Venus Remedies Limited will have a strong presence in South Korean Pharmaceutical market and the company is looking for such more deals in near future.